DUBLIN--(http://www.researchandmarkets.com/research/8drjft/global) has announced the addition of the "Global Dyslipidemia Epidemiology and Patient Flow Analysis - 2012" report to their offering.)--Research and Markets (
“Global Dyslipidemia Epidemiology and Patient Flow Analysis - 2012”
Fore Pharma announced the results of its Dyslipidemia patient population study in a new report Global Dyslipidemia Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Dyslipidemia epidemiology, Dyslipidemia diagnosed patients, and Dyslipidemia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Dyslipidemia derived from epidemiological analysis, percentage of patients diagnosed with Dyslipidemia, and percentage of patients treated with Dyslipidemia therapy.
The study helps executives estimate Dyslipidemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Dyslipidemia prevalence, Dyslipidemia diagnosis rate, and Dyslipidemia treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
Key Features of the Report:
- Dyslipidemia: Disease Definition
- Dyslipidemia Patient Flow
- Dyslipidemia Prevalence
- Dyslipidemia Diagnosed Patients
- Dyslipidemia Treated Patients
For more information visit http://www.researchandmarkets.com/research/8drjft/global